The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Options for Poliomyelitis Vaccination in the United States: Workshop Summary
Martin WJ, Ahmed KN, Zeng LC, Olsen JC, Seward JG, Seehrai JS. African green monkey origin of the atypical cytopathic “stealth virus” isolated from a patient with chronic fatigue syndrome. Clinical and Diagnostic Virology 1995; 4:93–103.
McBean AM, Thomas ML, Albrecht P et al. Serologic response to oral polio vaccine and enhanced-potency inactivated polio vaccines. American Journal of Epidemiology 1988; 128:615.
Nkowane BM, Wassilak SGF, Orenstein WA et al. Vaccine-associated paralytic poliomyelitis. United States: 1973 through 1984. Journal of the American Medical Association 1987; 257:1335–1340.
Onorato IM, Modlin JF, McBean AM, Thoms ML, Losonsky GA, Bernier RH. Mucosal immunity induced by enhanced potency inactivated and oral polio vaccines. Journal of Infectious Diseases 1991; 163:1–6.
Plotkin SA, Mortimer EA, eds. Vaccines, 2nd edition. New York: W.B. Saunders Company; 1994. (See especially chapters 1, 6, 7, and 8)
Strebel PM, Sutter RW, Cochi SL, Biellik RJ, Brink EW, Kew OM, Pallansch MA, Orenstein WA, Hinman AR. Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clinical Infectious Diseases 1992; 14:568–579.
Sutter R and Patriarca P. Inactivated and live, attenuated poliovirus vaccines: mucosal immunity. In: Kurstak E, ed. Measles and Poliomyelitis. Springer-Verlag; 1993.